✦ LIBER ✦

Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?

✍ Scribed by Ruiz-Argüelles, G J; Tarin-Arzaga, L C; Gonzalez-Carrillo, M L; Gutierrez-Riveroll, K I; Rangel-Malo, R; Gutiérrez-Aguirre, C H; Cantú-Rodríguez, O G; Gómez-Almaguer, D; Giralt, S

Book ID: 109840668
Publisher: Nature Publishing Group
Year: 2008
Tongue: English
Weight: 142 KB
Volume: 42
Category: Article
ISSN: 0007-1188
DOI: 10.1038/bmt.2008.90

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

157: Therapeutic Choices in Patients wit

157: Therapeutic Choices in Patients with Ph1 (+) Chronic Myelogenous Leukemia Living in Developing Countries in the Tyrosine Kinase Inhibitors (TKI) Era: Stem Cell Transplantation or TKI?

✍ G.J. Ruiz-Arguelles; L.C. Tarin-Arzaga; M.L. Gonzalez-Carrillo; K.I. Gutierrez-R 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Outcome of patients with CML after SCT i

Outcome of patients with CML after SCT in the era of tyrosine kinase inhibitors

✍ Saußele, S; Hehlmann, R; Gratwohl, A; Hochhaus, A 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 116 KB

Cost-Consequence Analysis of a Treatment

Cost-Consequence Analysis of a Treatment Strategy Including Ponatinib Compared to a Treatment Strategy Including Only the 2nd Generation Tyrosine Kinase Inhibitors (2g TKIs), Dasatinib or Nilotinib, in Resistant Patients with Philadelphia Chromosome-Positive (Ph+) Leukemia, in Italy

✍ Chiroli, S.; Furneri, G.; Pane, F. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB